Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632
THE FUTURE OF SFA TREATMENT: NEW TECHNOLOGIES
Bosiers M. 1, Deloose K. 1, Keirse K. 2, Verbist J. 2, Peeters P. 2
1 Department of Vascular Surgery, AZ St-Blasius, Dendermonde, Belgium;
2 Department of Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium
Drug-eluting stent (DES) technology was developed to prevent early thrombosis and late luminal loss to potentially improve long-term patency rates. Although favorable DES results have recently become available with the Zilver® PTX™ and STRIDES studies, the high price of DES is a major drawback for this technology to become the golden standard for peripheral endovascular therapy in de novo femoro-popliteal (FP) lesions. Nevertheless, DES has the potential to make the difference and to establish itself as an important treatment option in patients presenting with TASC C&D FP lesions who are at high-risk for surgery and for the treatment of in-stent restenosis, where until now, no valuable treatment option has proven to be beneficial.